It’s noteworthy here that our findings regarding the potential prognostic value of ADAM6, at least to some extent, corroborate the previous findings by Alsuwaidi and coworkers who reported the association of ADAM6 gene homozygous deletions with a poor ten years of overall patients’ survival in B-ALL patients [20]. This evidence concerns the gene ADAM6 and acute lymphoblastic leukemia.